Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes (1 of 3)
Program Overview
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Faculty
Michael E. Wechsler, MD, MMSc
Professor, Medicine Director, Cohen Family NJH Asthma Institute Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO